Whoever he is, I did like his pointed question. "What the heck were y'all thinking with that offering?" was spot on. To hear MNTA's thought process on why they did it (being tremendously conservative and assuming everything that could go wrong, would) was useful. If MNTA is so well prepared and conservative on their analytics and preparation for generic Copaxone, and are still publicly thinking the application is approvable as is, gives one reason to feel confident.
Added more shares this AM. Thanks to whomever sold.
Market Data 
Markets 
AI
